ClinicalTrials.gg

Program

prulacabtagene leucel

Its studies are mostly in Lupus Nephritis · Arthritis, Rheumatoid, led by Adicet Therapeutics.

Furthest: phase 1, since Apr 17, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Adicet Therapeutics22 open or runningphase 1since Apr 17, 2024Apr 17, 2024Dec 2026phase 1 · NCT06375993

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2024First study: phase 1 study in Lupus NephritisFirst studyNCT06375993 · 180 planned · United States
  2. Jul 28, 2025Phase 1 study in Arthritis, RheumatoidNCT07100873 · 25 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in Lupus NephritisNCT06375993
  2. Mar 30, 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT07100873

TargetBeta

MS4A1 →read by rule
“A preparation of a subset of allogeneic T-lymphocytes that express only gamma chain and delta chain T-cell receptors (TCRs) and that are engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD20 (cluster of differentiation 20), ”NCIt, by rule

Other programs on MS4A1

ProgramCompanyFurthest phaseStudies
RituximabruleHoffmann-La Rochephase 4175
ocrelizumabruleHoffmann-La Rochephase 442
obinutuzumabruleHoffmann-La Rochephase 442
ublituximabruleTG Therapeuticsphase 323
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
Anti-CD20 Monoclonal Antibody MIL62rulebeijing-mabworks-biotech-co-ltdphase 310
odronextamabruleRegeneron Pharmaceuticalsphase 38
TQB2825Sino Biopharmaceuticalphase 35
zuberitamabrulebioray-pharmaceutical-co-ltdphase 33
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07100873Arthritis, Rheumatoid · China1RecruitingMar 30, 202725
NCT06375993Lupus Nephritis · United States1By invitationDec 2026180

How it is read

Names in the registry

  • “ADI-001”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.